Sign in
4

Changes in Ownership

NEKTAR THERAPEUTICS Filed Acc 0001209191-21-065229

Chief R&D Officer sold 20,869 shares at $13.16 ($274,636)

  • Chief R&D Officer acquired 40,150 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Zalevsky Jonathan Chief R&D Officer 2021-11-15 Grant or award +40,150 252,953 D: show line 1 in the form
Zalevsky Jonathan Chief R&D Officer 2021-11-16 Sale −20,869 $13.16 $274,636 232,084 D: show line 2 in the form
Open-market sales · 20,869 sh · avg $13.16 · $274,636
Loading xslF345X03/doc4.xml…